Results 161 to 170 of about 21,275,692 (207)

Therapy of non-small cell lung cancer [PDF]

Lung Cancer, 1995
Several regimes can provide clinical answers and longer survival to patients with small cell carcinoma of the lungs who respond to treatment. Moreover there is frequently also suppression of pathological symptoms of the disease in these patients.
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Bevacizumab in Non-Small Cell Lung Cancer

Drugs, 2008
Lung cancer continues to be the leading cause of cancer death in Western countries. The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor and chemotherapy is the treatment of choice for most patients with metastatic NSCLC. Platinum-based chemotherapy has long been the standard of care for advanced NSCLC. The formation of
Di Costanzo F., Mazzoni F., Micol Mela M., Antonuzzo L., Checcacci D., Saggese M., Di Costanzo F.   +6 more
openaire   +2 more sources

Anthacyclines in non-small cell lung cancer

Lung Cancer, 2001
The literature concerning the use of anthracyclines in the treatment of non-small cell lung cancer (NSCLC) is reviewed here. Overall, the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-high doses.
P, Pronzato, A, Vigani, A, Tognoni, F, Vaira, P, Canessa   +4 more
openaire   +2 more sources

Non-small-cell lung cancer

Nature Reviews Disease Primers
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and ...
Lizza E. L. Hendriks, Jordi Remon, Corinne Faivre-Finn, Marina C. Garassino, John V. Heymach, Keith M. Kerr, Daniel S. W. Tan, Giulia Veronesi, Martin Reck   +8 more
openaire   +3 more sources

Pneumonectomy for non-small cell lung cancer

Surgery Today, 2012
To assess the mortality, complications and major morbidity of pneumonectomy for non-small cell lung cancer (NSCLC) and to establish the importance of various prognostic factors.We reviewed retrospectively the hospital records of 71 consecutive patients who underwent pneumonectomy for NSCLC between 1992 and 2007 to evaluate the significance of risk ...
Yoshinobu, Ichiki, Akira, Nagashima, Yasuhiro, Chikaishi, Manabu, Yasuda   +3 more
openaire   +2 more sources

Vinorelbine for non-small cell lung cancer

Expert Opinion on Drug Safety, 2010
Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs.
Maria Carmela, Piccirillo, Gennaro, Daniele, Massimo, Di Maio, Jane, Bryce, Gianfranco, De Feo, Antonia, Del Giudice, Francesco, Perrone, Alessandro, Morabito   +7 more
openaire   +2 more sources

Gemcitabine in non-small cell lung cancer

Lung Cancer, 1995
The pyrimidine antimetabolite gemcitabine is an analogue of cytosine arabinosid. Gemcitabine is well tolerated when given in doses of 1000-1250 mg/m2 weekly x 3 followed by 1 weeks rest, with mild myelosuppression as the major toxicity. In five studies, including a total of 250 patients with previously untreated non-small cell lung cancer (NSCLC ...
openaire   +2 more sources

Immunotherapy for non-small-cell lung cancer

Expert Opinion on Biological Therapy, 2014
Activation of the host immune system represents an attractive treatment approach for cancers. In non-small-cell lung cancer (NSCLC), a variety of immunotherapies, including nonspecific immune stimulants, vaccines and checkpoint inhibitors, have been evaluated in clinical trials.
Thomas, Anish, Jakopović, Marko
openaire   +3 more sources

Necitumumab for non-small cell lung cancer

Expert Opinion on Biological Therapy, 2015
Targeting the EGFR pathway is a rational approach to treat patients with advanced NSCLC. Necitumumab, a second-generation recombinant fully human immunoglobulin G1 monoclonal antibody directed against EGFR, has recently been assessed in combination with first-line cisplatin-based chemotherapy.This article reviews literature on necitumumab development ...
Laurent, Greillier, Pascale, Tomasini, Fabrice, Barlesi   +2 more
openaire   +2 more sources

Angiogenesis in non-small cell lung cancer

Seminars in Thoracic and Cardiovascular Surgery, 2004
Two processes are necessary for a tumor colony to grow and become invasive: angiogenesis and basement membrane degradation. Angiogenesis is the formation of new blood vessels from the endothelium of existing vasculature, in response to the metabolic demand of the tumor.
openaire   +2 more sources